A 35-year-old woman with polycystic ovary syndrome (PCOS) presents with endometrial hyperplasia on biopsy due to unopposed estrogen exposure. In contrast, a 28-year-old woman with chronic iron deficiency anemia has compensatory erythroid hyperplasia in her bone marrow. Which finding best distinguishes pathologic endometrial hyperplasia from physiologic erythroid hyperplasia?

Question

Accepted Answer

C. Risk of malignant transformation and architectural disorganization. ## Pathologic vs. Physiologic Hyperplasia: The Critical Distinction

### Definition and Core Difference

**Key Point:** Pathologic hyperplasia (endometrial) carries risk of malignant transformation and shows loss of normal tissue architecture, whereas physiologic hyperplasia (erythroid) is a controlled, reversible response that does not predispose to cancer.

### Comparison Table

| Feature | Pathologic Hyperplasia (Endometrial) | Physiologic Hyperplasia (Erythroid) |
| --- | --- | --- |
| **Stimulus** | Unopposed estrogen (maladaptive) | Hypoxia / anemia (adaptive) |
| **Architecture** | Disorganized, crowded glands | Organized, normal maturation sequence |
| **Malignant potential** | YES (5–30% progress to cancer) | NO |
| **Reversibility** | Partial (atypical hyperplasia may persist) | Complete (resolves with iron repletion) |
| **Nuclear features** | Hyperchromatic, irregular, increased N:C ratio | Normal, progressive maturation |
| **Outcome** | Endometrial cancer risk | Return to normal hematopoiesis |

### Pathologic Endometrial Hyperplasia

1. **Stimulus:** Chronic unopposed estrogen (PCOS, obesity, exogenous estrogen)
2. **Mechanism:** Estrogen stimulates proliferation without progesterone-mediated differentiation and apoptosis
3. **Histology:** Crowded, disorganized glands; loss of normal spacing; architectural atypia
4. **Risk:** Simple hyperplasia (1–3% malignant potential) → atypical hyperplasia (8–30% potential) → endometrial cancer
5. **Irreversibility:** Atypical changes may persist even after hormone withdrawal

### Physiologic Erythroid Hyperplasia

1. **Stimulus:** Chronic hypoxia from iron deficiency anemia (adaptive)
2. **Mechanism:** Erythropoietin (EPO) stimulates erythroid progenitors proportionally to oxygen demand
3. **Histology:** Organized maturation sequence; increased erythroid:myeloid ratio; normal nuclear features
4. **Risk:** NO malignant potential
5. **Reversibility:** Complete normalization upon iron repletion and hemoglobin restoration

**High-Yield:** The presence of architectural disorganization and malignant potential is the hallmark that separates pathologic from physiologic hyperplasia. Physiologic hyperplasia is always organized, controlled, and reversible.

**Mnemonic:** **PATHOLOGIC** = **P**roliferation with **A**rchitectural loss, **T**ransformation risk, **H**yperchromatic nuclei, **O**unopposed stimulus, **L**oss of control, **O**rgan dysfunction, **G**rowth beyond need, **I**rreversible changes, **C**ancer potential.

### Clinical Pearl

Endometrial hyperplasia with atypia is a precancerous lesion requiring treatment (progestin therapy or hysterectomy), whereas erythroid hyperplasia in anemia is a normal compensatory response requiring only iron supplementation. This distinction is critical for clinical management.

![Cellular Adaptations — Hyperplasia, Hypertrophy diagram](https://mmcphlazjonnzmdysowq.supabase.co/storage/v1/object/public/blog-images/explanation/2804.webp)

Answer

A. Reversibility when the causative stimulus is removed

Answer

B. Hyperchromatic nuclei and increased mitotic activity

Answer

D. Increased number of cells in response to a stimulus

Explanation

Pathologic vs. Physiologic Hyperplasia: The Critical Distinction

Definition and Core Difference

Comparison Table

Pathologic Endometrial Hyperplasia

Physiologic Erythroid Hyperplasia

Clinical Pearl

Practice similar questions

Join our NEET PG community

Feature	Pathologic Hyperplasia (Endometrial)	Physiologic Hyperplasia (Erythroid)
Stimulus	Unopposed estrogen (maladaptive)	Hypoxia / anemia (adaptive)
Architecture	Disorganized, crowded glands	Organized, normal maturation sequence
Malignant potential	YES (5–30% progress to cancer)	NO
Reversibility	Partial (atypical hyperplasia may persist)	Complete (resolves with iron repletion)
Nuclear features	Hyperchromatic, irregular, increased N:C ratio	Normal, progressive maturation
Outcome	Endometrial cancer risk	Return to normal hematopoiesis